Dr. Ellis-Behnke is the inventing cofounder and a scientific advisor to Arch Therapeutics. His discovery of the immediate hemostasis technology while he was at MIT led to the founding of the company. He holds 10 U.S. patents for multiple discoveries that use nanotechnology to help repair the body, ranging from immediate hemostasis; repairing the optic nerve and demonstrating the reversal of blindness; preserving stem cells; and immobilizing cancer stem cells. Dr. Ellis-Behnke holds affiliate faculty positions at MIT and the University of South Florida Morgani College of Medicine. From 2010 to 2015 he was Director of the Nanotechnology Translational Think Tank in the Mannheim Medical Faculty of the University of Heidelberg in Germany; from 2004 to 2010 he was in the Faculty of Medicine at the University of Hong Kong first as a Research Associate from 2004 to 2006, then as Associate Professor and concurrently Associate Director of the Technology Transfer Office from 2007 to 2010. Prior to returning to MIT to pursue his PhD in 1998, he held various management positions including Senior Vice President of Huntingdon, a public company for pharmaceutical testing and consulting services. In 1995, he became co-founder/CEO of one of the first internet companies in the world to do online commerce. Dr. Ellis-Behnke received his PhD from MIT in Neuroscience in 2003; his BS from Rutgers in Agricultural Sciences in 1984 and a diploma from Harvard Business School’s Advanced Manager’s Program in 1995. From 2006 to 2015 he was the Associate Editor/Neurology for Nanomedicine: Nanotechnology, Biology & Medicine. He is a member of the National Academy of Inventers and a life member of the International Society of Nanomedicine.
Shri Parikh, an advisor to Arch, brings over 28 years of wide ranging healthcare expertise. Mr. Parikh started his professional career with Bristol-Myers Squibb Pharmaceuticals where he eventually had marketing and sales leadership positions. He subsequently moved to St. Jude Medical, as Vice President, Strategic Corporate Sales and National & Government Accounts, and then to Stryker, where he where he was responsible for national GPO sales and strategic field execution and contracting for the Stryker MedSurg businesses. In 2013, he moved to Mölnlycke, where he was Vice President of Sales, Marketing and Corporate Accounts for the Surgical Portfolio with responsibilities in the Wound Care and Surgical businesses for North America. He most recently served as President at Sanuwave Health. Mr. Parikh received a BA from Davidson College (Medical Ethics & Economics) and an MBA from Jacksonville University, and he has completed the Advanced Management Program at the University of Chicago.
Roger Gregory, PhD, Professor of Chemistry and Biochemistry, Kent State University, has been working with Arch Therapeutics since late 2011. He has provided expertise in product formulation and the relationship between the structure and properties of peptides. Dr. Gregory is a physical biochemist with over 30 years of experience in protein chemistry and analysis. His research interests include protein dynamics, protein hydration, and protein-solvent interactions. He recently returned to the Kent State faculty after serving over seven years as Chair of the Department of Chemistry. As Chair, he helped establish core facilities in genomics, proteomics, bioimaging and 3D visualization. Dr. Gregory earned his BSc and PhD in Biochemistry from the University of Sheffield, England, and performed his postdoctoral work in Protein Chemistry at the University of Minnesota.
John Richards, DPhil., who started advising Arch Therapeutics in 2016, brings over 30 years of pharmaceutical industry and peptide chemistry experience. Since 2009, he has been Vice President of Global Pharmaceutical Development at The Medicines Company, responsible for CMC development and manufacturing of all the company’s products, including the very large scale program for the peptide-based anticoagulant, Angiomax®. He has extensive experience leading CMC programs which have resulted in the successful filing and approval of drugs and biologics in the United States, European
Previous roles included Director of Process Development at ImmuLogic Pharmaceutical Corporation, where he was responsible for the design, construction and operation of a multi-train peptide manufacturing facility, and Manager of Peptide Synthesis at UK start-up Cambridge Research Biochemicals and its
He earned his doctorate developing protecting groups for use in peptide synthesis at The University of Oxford. While performing his Post-Doctoral work in the Laboratory of Molecular Biology, Cambridge, UK, he was a member of Dr. Robert Sheppard's team that developed the Fmoc-solid phase method of peptide synthesis.
Dr. Denman started advising Arch Therapeutics in 2012. He is a Massachusetts General Hospital Anesthesiologist, Clinical Trial Investigator and past Chief Medical Officer of Covidien and GE Healthcare.
Dr. Denman received his medical training in the United Kingdom, completing residency at St. Bartholomew’s Hospital in London, followed by a fellowship at Massachusetts General Hospital, remaining on staff. In 2000 he became Chief of Pediatric Anesthesia at the Floating Hospital for Children in Boston. During his full-time medical practice he was involved in multiple clinical trials and development of pharmaceuticals and devices. He filed and was awarded several patents while focusing on solutions for unmet clinical needs.
In 2003, he began his career at Tyco Healthcare, now Covidien, becoming the Chief Medical Officer and VP for Medical Affairs in 2007. He guided development and implementation of the medical functions throughout Covidien, built a medical affairs, clinical affairs, healthcare economics and reimbursement team; focused these functions on ensuring compliance with new regulations and driving the medical voice into all aspects of the business. From 2010 to 2012, he was the Chief Medical Officer at GE Healthcare. In this role he strove to ensure a patient-centered culture while focusing on healthcare providers and his team was embedded in all facets of the business; R&D, clinical trials, training, compliance, business development and risk management.
He continues a clinical practice at Massachusetts General Hospital and an academic affiliation at Harvard Medical School, both in Boston. He continues to publish and has recently been granted several more patents. He is co-leader of an annual mission to Vietnam where he provides care to children and medical teaching to those who care for children.
Steve Schwaitzberg, MD, FACS, is an advisor to Arch, bringing his expertise in surgery, clinical trials, and biomaterials for hemostasis and sealing. He is Professor of and Chairman the Department of Surgery for the University at Buffalo - Jacobs School of Medicine and Biomedical Sciences. Formerly he was the Chief of Surgery at Cambridge Health Alliance, adjunct professor at Tufts University, and Professor of surgery at Harvard Medical School. He is Past President of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES), a world-class laparoscopic surgical association.
A key opinion leader, Dr. Schwaitzberg has a distinguished reputation in surgery. He was initially trained as a trauma and surgical infection expert and then became an early leader in the minimally invasive surgery (MIS) revolution. Dr. Schwaitzberg is an innovator who teaches surgical technique around the world. He has served in key leaderships positions in major surgical organizations and received international recognition as a leader in technology in the operating room and for the introduction of novel MIS technology.
Dr. Schwaitzberg is a seasoned clinical researcher who also served as the Chairman of the Tufts University School of Medicine and Medical Center institutional review Board. He has a deep interest in technology development. He is widely published and has been invited to present and teach courses around the world for over 25 years. Dr. Schwaitzberg earned an MD from Baylor College of Medicine, a MA from Harvard medical School and a BA in biology from The Johns Hopkins University.
Dr. Austen, an advisor to Arch as of 2020, is Chief of the Plastic and Reconstructive Surgery Division and Chief of Burn Surgery at Massachusetts General Hospital; Professor of Surgery at Harvard Medical School; Director of the Aesthetic and Reconstructive Breast Fellowship Program; and Mass General Trustee Chair of Plastic and Reconstructive Surgery. He received his undergraduate degree at Princeton followed by his medical degree at Harvard Medical School. Dr. Austen trained in General Surgery and Plastic Surgery at the Harvard Medical School and completed a Fellowship in Craniofacial Surgery at the Royal Children’s Hospital in Melbourne, Australia. Dr. Austen is a member of numerous societies including the Society of University Surgeons, the American College of Surgeons, the American Association of Plastic Surgeons, the ASPS, and the Migraine Surgery Council.
Dr. Austen has a diverse clinical practice that spans aesthetic and reconstructive surgery. He is an authority in the new field of the surgical treatment of migraine headaches. The focus of his laboratory is on translational research, particularly in fat regeneration, vascular biology, and device development.
Dr Austen has a long history of innovation in outcomes and basic science. He is founder of Cytrellis Bio-Systems and Auragen Aesthetics, both companies based on his innovations. He has authored more than 100 papers and holds numerous patents. Dr. Austen has won numerous awards including Teacher of the Year in Plastic Surgery training program at the Harvard Medical School and Experimental Paper of the Year 2015 in Plastic and Reconstructive Surgery, the Journal of the American Society of Plastic Surgeons.
Dr. Daniel Kapp, an advisor to Arch as of 2019, is a Board Certified Plastic Surgeon. He is currently the Chief of Plastic Surgery at Palm Beach Gardens Medical Center where he previously served as the Chief of Surgery. Dr. Kapp is also the Medical Director of the Wound Healing Center at Jupiter Medical Center. He has served as an advisor to a number of pharmaceutical and medical device manufacturers and is currently a key Scientific Advisor to Recros Medica. Dr. Kapp was a founding partner and has served on the Medical Advisory Board of MDLive, one of the nation’s largest telemedicine providers since its 2009 inception. He is a partner and founder of Injecture and Conjecture, which focuses on insurance for cosmetic applications. Kapp has been involved in product development from design to launch. Dr. Kapp is a graduate of the University of Virginia. He completed medical school at the University of South Florida and Plastic Surgery Residency at the Ohio State University. He was the Anastasi Fellow in Plastic Surgery at Boston University.
Dr. Dhillon is an advisor to Arch Therapeutics. He previously served as Chairman of the Board of Directors of Arch from April 2013 to July 2018. He has more than 25 years of experience in building public life science companies organically and through mergers and acquisitions, leading innovation in scientific, engineering and agricultural enterprises, securing significant United States government grants and NGO funding, raising significant investment proceeds from US, Canadian, European and Asian institutions and high net worth individuals, and building dominant IP portfolios through partnering and negotiating transactions with small businesses and large multibillion dollar companies. Dr. Dhillon is a successful executive and entrepreneur who has been instrumental in founding, helping develop and leading a number of companies including, Inovio Pharmaceuticals (NASDAQ: INO), which develops next-generation DNA based vaccines, where he was President and Chief Executive Officer from October 2001 to June 2009, Executive Chairman from June 2009 to August 2011, and Chairman since September 2011; OncoSec Biomedical (NASDAQ: ONCS), which develops DNA-based intratumoral cancer immunotherapies, where he has been Chairman of the Board since inception in 2011; Vitality Biopharma (OTCQB: VBIO), where he served as Chairman of the Board since January 2012; and Emerald Health Therapeutics (TSX.V: EMH), where he has been Chairman of the Board since April 2015.
Previously, Dr. Dhillon was vice president of MDS Capital Corp., one of North America's leading healthcare venture capital organizations. He completed B.Sc. (Honors) and M.D. degrees at the University of British Columbia and practiced family medicine for 12 years from June 1989 to December 2001.
Steven Kates, PhD has worked with Arch Therapeutics since 2007. He is a highly experienced pharmaceutical executive with over twenty years in R&D for both life science products and human therapeutics, Dr. Kates is regarded as a world leading chemist and industry expert in peptide design and manufacture in the biopharmaceutical industry. He has advanced several compounds through drug development from early pre-clinical to early clinical development. He was responsible for the successful development of clinical candidates for both 505(b)2 and NCE applications. He has held senior positions at Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation.
Dr. Kates has authored or co-authored over 100 articles, reviews, and patents, and is a member of the American Chemical Society, the American Peptide Society, and the Association of BioMolecular Research Facilities. Dr. Kates has served as editor of Solid-Phase Synthesis: A Practical Guide and ADMET for Medicinal Chemists: A Practical Guide; guest editor of Biopolymers; co-editor of ADMET for Medicinal Chemists, A Practical Guide; a member of the Editorial Board of International Journal of Peptide Research and Therapeutics (formerly Letters in Peptide Science); and is an ad hoc reviewer for the NIH bio-organic and natural products study section.
An Adjunct Professor in the Bouvé College of Health and Sciences, Center for Drug Discovery and College of Professional Studies at Northeastern University, and Visiting Professor of Chemistry at Brandeis University, Dr. Kates earned his B.S. in chemistry from Bates College and his PhD in Synthetic Organic Chemistry from Brandeis University, and conducted post-doctoral studies at The Massachusetts Institute of Technology. His research interests include solid-phase peptide and organic synthesis as well as synthesis of peptides and small molecules with therapeutic activities for stroke, coronary artery bypass graft (CABG), myocardial infarction (MI) and inhibitors and substrates for kinases, proteases and G-protein coupled receptors.
Dr. Dmitry Nepomnayshy, an advisor to Arch since 2019, is a senior surgeon in the department of general surgery at the Lahey Hospital and Medical Center in Burlington, MA and Associate Professor of Surgery at the Tufts University College of Medicine in Boston, MA. He is the Director of Professional Development and Simulation at Lahey Hospital, as well as the Director of the Bariatric Surgery Fellowship, and Associate Program Director of the General Surgery Residency program. His clinical specialty includes bariatric and minimally invasive surgery. Dr. Nepomnayshy's research interests involve education where he leads an international effort to develop the first expert level curriculum in laparoscopic surgery, the Advanced Laparoscopic Surgery curriculum (ALS), and he performs both clinical and translational research on bariatric surgery.
Dr. Nepomnayshy completed a Masters of Science degree at McGill University with an emphasis on surgical education. He has been recognized as a dedicated educator and clinician as a recipient of multiple awards. Dr. Nepomnayshy is active in several surgical societies, including leadership roles in the Massachusetts Chapter of the American College of Surgeons and the Boston Surgical Society, as well as committee roles in the Society of American Gastrointestinal and Endoscopic Surgeons, the American College of Surgeons Accredited Institutes Consortium, and the Association of Surgical Education.
Dr. Nepomnayshy earned an MD from Ohio State University College of Medicine and an MS in Experimental Surgery with an emphasis on surgical education from McGill University. In 2001, he completed his general surgery residency at Lahey Clinic in Burlington, MA.
Elaine Whitmore, PhD, brings over 25 years of extensive history in the medical products industry to Arch Therapeutics, with whom she started working in late 2010 focusing on regulatory planning and strategy. In addition to regulatory submissions, Dr. Whitmore’s experience includes development, testing, technology evaluation, and clinical planning for a variety of hemostasis products (fibrin sealants; bovine, human and recombinant thrombin products; cellulose; collagen; etc.), adhesion prevention products, and infection prevention products.
Dr. Whitmore is the author of Development of FDA-Regulated Medical Products—A Translational Approach (ASQ Quality Press, 2012) and has numerous patents for medical product technologies. Prior to becoming a product development and technology consultant, she held executive management industry positions in a variety of functions, including New Product Development, Regulatory and Clinical Affairs, Scientific Affairs, and Business Development. Dr. Whitmore received her PhD degree from Northwestern University.